UK’s MHRA approves Beyfortus to prevent respiratory syncytial virus in infants
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has given approval to Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season
About 90% of children by the age of two get infected by RSV, which is a common and contagious seasonal virus.
Jointly developed by Sanofi and AstraZeneca, nirsevimab is claimed to be the first and only single-dose RSV protective option for wide infant population, including those who are born healthy, at term or preterm, or even with particular health conditions.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins